产品编号：L175500
产品规格：25mg
产品价格：面议
| 标准品编号: | L175500 |
| 名称: | Lapaquistat Acetate |
| 别名: | 1-[2-[(3R,5S)-1-[3-(Acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidineacetic Acid; (3R-trans)-1-[[1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidineacetic Acid; TAK 475; |
| CAS号: | 189060-13-7 |
| 分子式: | C₃₃H₄₁ClN₂O₉ |
| 外观: | 白色固体 |
| 熔点: | >180ºC (dec.) |
| 分子量: | 645.14 |
| 溶解度: | Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) |
| 种类: | Standards; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites; |
| 应用: | A novel squalene synthase inhibitor. Lapaquistat acetate decreased plasma cholesterol and triglyceride levels, by lowering lipoproteins containing apoB100. Treatment with Lapaquistat acetate increased collagen concentration and transformed coronary plaques into fibromuscular plaques. Lapaquistat acetate also suppressed the expression of matrix metalloproteinase-1 and plasminogen activator inhibitor-1 in the plaque and increased peripheral coenzyme Q10 levels. Antiarteriosclerotics. |
| 参考文献 | |
